The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain
Abstract
A major feature of Alzheimer's disease is the accumulation of amyloid-beta peptide (Abeta) in the brain both in the form of plaques in the cerebral cortex and in blood vessel as cerebral amyloid angiopathy (CAA). Experimental models and human clinical trials have shown that accumulation of Abeta plaques can be reversed by immunotherapy. In this study, we hypothesized that Abeta in plaques is solubilized by antibodies generated by immunization and drains via the perivascular pathway, detectable as an increase in cerebrovascular Abeta. We have performed a follow up study of Alzheimer's disease patients immunized against Abeta42. Neuropathological examination was performed on nine patients who died between four months and five years after their first immunization. Immunostaining for Abeta40 and Abeta42 was quantified and compared with that in unimmunized Alzheimer's disease controls (n = 11). Overall, compared with these controls, the group of immunized patients had approximately 14 times as many blood vessels containing Abeta42 in the cerebral cortex (P<0.001) and seven times more in the leptomeninges (P = 0.013); among the affected blood vessels in the immunized cases, most of them had full thickness and full circumference involvement of the vessel wall in the cortex (P = 0.001), and in the leptomeninges (P = 0.015). There was also a significantly higher level of cerebrovascular Abeta40 in the immunized cases than in the unimmunized cases (cortex: P = 0.009 and leptomeninges: P = 0.002). In addition, the immunized patients showed a higher density of cortical microhaemorrhages and microvascular lesions than the unimmunized controls, though none had major CAA-related intracerebral haemorrhages. The changes in cerebral vascular Abeta load did not appear to substantially influence the structural proteins of the blood vessels. Unlike most of the immunized patients, two of the longest survivors, four to five years after first immunization, had virtually complete absence of both plaques and CAA, raising the possibility that, given time, Abeta is eventually cleared from the cerebral vasculature. The findings are consistent with the hypothesis that Abeta immunization results in solubilization of plaque Abeta42 which, at least in part, exits the brain via the perivascular pathway, causing a transient increase in the severity of CAA. The extent to which these vascular alterations following Abeta immunization in Alzheimer's disease are reflected in changes in cognitive function remains to be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“Immunization strategies in mice can also neutralize the Ab oligomers, which current evidence suggests are a particularly neurotoxic form of Ab (Klyubin et al., 2005; Lesne et al., 2006).”
BackgroundRetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,498
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Self-citationShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
(1964) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1964.tb115841.x · Cited by 1,409
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Self-citationSubacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Transforming Growth Factor-β: Biological Function and Chemical Structure
Sporn, M. B., Roberts, A. B., Wakefield, L. M., & Assoian, R. K. (1986) · Science · doi:10.1126/science.3487831 · Cited by 1,182
Cerebral microvascular pathology in aging and Alzheimer's disease
Farkas, E., & Luiten, P. G. M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00068-x · Cited by 1,102
Cerebral amyloid angiopathy. A critical review.
Vinters, H. V. (1987) · Stroke · doi:10.1161/01.str.18.2.311 · Cited by 1,071
Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858
Roher, A. E., Lowenson, J. D., Clarke, S., Wolkow, C., Wang, R., Cotter, R. J., Reardon, I. M., Zürcher-Neely, H. A., Heinrikson, R. L., & Ball, M. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53661-9 · Cited by 799
Weller, R. O., Subash, M., Preston, S. D., Mazanti, I., & Carare, R. O. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00133.x · Cited by 681
Self-citationWeller, R. O., Massey, A., Newman, T. A., Hutchings, M., Kuo, Y.-M., & Roher, A. E. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65616-7 · Cited by 679
Self-citationAmyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676 · cited 2×
“We specifically studied the effects of immunization on the distribution of Ab42 in relation to the vasculature, as in Alzheimer’s disease Ab42 is predominantly located in plaques with very little in the vasculature (Roher et al., 1993; Gravina et al., 1995).”
BackgroundCarare, R. O., Bernardes‐Silva, M., Newman, T. A., Page, A. M., Nicoll, J. A. R., Perry, V. H., & Weller, R. O. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00926.x · Cited by 665
Self-citationTGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice
Wyss-Coray, T., Lin, C., Yan, F., Yu, G.-Q., Rohde, M., McConlogue, L., Masliah, E., & Mucke, L. (2001) · Nature Medicine · doi:10.1038/87945 · Cited by 587
Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy
Greenberg, S. M., William Rebeck, G., Vonsattel, J. P. G., Gomez‐Isla, T., & Hyman, B. T. (1995) · Annals of Neurology · doi:10.1002/ana.410380219 · Cited by 541
(1997) · doi:10.1073/pnas.94.4.1550 · Cited by 535
Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy
Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M., & Jucker, M. (2002) · Science · doi:10.1126/science.1078259 · Cited by 511
Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo
Klyubin, I., Walsh, D. M., Lemere, C. A., Cullen, W. K., Shankar, G. M., Betts, V., Spooner, E. T., Jiang, L., Anwyl, R., Selkoe, D. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1234 · Cited by 489
Ferrer, I., Rovira, M. B., Guerra, M. L. S., Rey, M. J., & Costa‐Jussá, F. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00493.x · Cited by 479
Bacskai, B. J., Kajdasz, S. T., Christie, R. H., Carter, C., Games, D., Seubert, P., Schenk, D., & Hyman, B. T. (2001) · Nature Medicine · doi:10.1038/85525 · Cited by 449
Two Types of Sporadic Cerebral Amyloid Angiopathy
Thal, D. R., Ghebremedhin, E., Rüb, U., Yamaguchi, H., Del Tredici, K., & Braak, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.3.282 · Cited by 446
Clinical manifestations of cerebral amyloid angiopathy–related inflammation
Eng, J. A., Frosch, M. P., Choi, K., Rebeck, G. W., & Greenberg, S. M. (2004) · Annals of Neurology · doi:10.1002/ana.10810 · Cited by 417
Wilcock, D. M., Rojiani, A. M., Rosenthal, A., Subbarao, S., Freeman, M. J., Gordon, M. N., & Morgan, D. (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-24 · Cited by 397
Scolding, N. J. (2005) · Brain · doi:10.1093/brain/awh379 · Cited by 372
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
Bayer, A. J., Bullock, R., Jones, R. W., Wilkinson, D., Paterson, K. R., Jenkins, L., Millais, S. B., & Donoghue, S. (2005) · Neurology · doi:10.1212/01.wnl.0000148604.77591.67 · Cited by 356
Self-citationAβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease
Masliah, E., Hansen, L., Adame, A., Crews, L., Bard, F., Lee, C., Seubert, P., Games, D., Kirby, L., & Schenk, D. (2005) · Neurology · doi:10.1212/01.wnl.0000148590.39911.df · Cited by 353
Premkumar, D. R., Cohen, D., Hedera, P., Friedland, R. P., & Kalaria, R. N. (1996) · Europe PMC (PubMed Central) · Cited by 348
Wilcock, D. M., Rojiani, A., Rosenthal, A., Levkowitz, G., Subbarao, S., Alamed, J., Wilson, D., Wilson, N., Freeman, M. J., Gordon, M. N., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1090-04.2004 · Cited by 299
Spontaneous Hemorrhagic Stroke in a Mouse Model of Cerebral Amyloid Angiopathy
Winkler, D. T., Bondolfi, L., Herzig, M. C., Jann, L., Calhoun, M. E., Wiederhold, K.-H., Tolnay, M., Staufenbiel, M., & Jucker, M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01619.2001 · Cited by 287
Reply to: 'Clearance of amyloid β-peptide from brain: transport or metabolism?'
Iwata, N., Tsubuki, S., Hama, E., Takaki, Y., Shirotani, K., & Saido, T. C. (2000) · Nature Medicine · doi:10.1038/77399 · Cited by 285
Aβ Species Removal After Aβ 42 Immunization
Nicoll, J. A. R., Barton, E., Boche, D., Neal, J. W., Ferrer, I., Thompson, P., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., et al. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000240466.10758.ce · Cited by 265
Self-citation5462925 Transforming growth factor beta2,3
(1996) · Biotechnology Advances · doi:10.1016/s0734-9750(97)81916-7 · Cited by 252
Wyss‐Coray, T., Feng, L., Masliah, E., Ruppe, M. D., Lee, H. S., Toggas, S. M., Rockenstein, E. M., & Mucke, L. (1995) · Europe PMC (PubMed Central) · Cited by 248
Duyckaerts, C., & Boller, F. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00603_6.x · Cited by 245
Cognitive and neurobiologic markers of early Alzheimer disease
Albert, M. S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13547 · Cited by 244
Preston, S. D., Steart, P. V., Wilkinson, A., Nicoll, J. A. R., & Weller, R. O. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00424.x · Cited by 239
Self-citationWilcock, D. M., DiCarlo, G., Henderson, D., Jackson, J., Clarke, K., Ugen, K. E., Gordon, M. N., & Morgan, D. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-09-03745.2003 · Cited by 232
Differential degeneration of the cerebral microvasculature in Alzheimerʼs disease
Kalaria, R. N., & Hedera, P. (1995) · NeuroReport · doi:10.1097/00001756-199502000-00018 · Cited by 216
Amyloid-β Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients
Patton, R. L., Kalback, W. M., Esh, C. L., Kokjohn, T. A., Van Vickle, G. D., Luehrs, D. C., Kuo, Y.-M., Lopez, J., Brune, D., Ferrer, I., et al. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.060269 · Cited by 192
Cerebral amyloid angiopathy: An overview
Yamada, M. (2000) · Neuropathology · doi:10.1046/j.1440-1789.2000.00268.x · Cited by 191
McDermott, J. R., & Gibson, A. M. (1997) · Neurochemical Research · doi:10.1023/a:1027325304203 · Cited by 187
Hellström-Lindahl, E., Ravid, R., & Nordberg, A. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.10.010 · Cited by 165
McCarron, M. O., Nicoll, J. A. R., Stewart, J., Ironside, J. W., Mann, D. M. A., Love, S., Graham, D. I., & Dewar, D. (1999) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199907000-00005 · Cited by 160
Self-citationCerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer’s disease
Nicoll, J. A. R., Yamada, M., Frackowiak, J., Mazur-Kolecka, B., & Weller, R. O. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.003 · Cited by 160
Self-citationChalmers, K., Wilcock, G. K., & Love, S. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00457.x · Cited by 156
Self-citationProgression of Cerebral Amyloid Angiopathy: Accumulation of Amyloid-ß40 in Affected Vessels
Alonzo, N. C., Hyman, B. T., Rebeck, G. W., & Greenberg, S. M. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199804000-00008 · Cited by 146
Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies
Lee, M., Bard, F., Johnson‐Wood, K., Lee, C., Hu, K., Griffith, S. G., Black, R. S., Schenk, D., & Seubert, P. A. (2005) · Annals of Neurology · doi:10.1002/ana.20592 · Cited by 132
Olichney, J., Hansen, L. A., Hofstetter, C. R., Lee, J. H., Katzman, R., & Thal, L. J. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.869 · Cited by 111
Pubertal Changes in Biochemical Markers of Growth
Federico, G., Baroncelli, G. I., Vanacore, T., Fiore, L., & Saggese, G. (2003) · Hormone Research in Paediatrics · doi:10.1159/000071225 · Cited by 102
Hyman, B. T., Strickland, D. K., & Rebeck, G. W. (2000) · Archives of Neurology · doi:10.1001/archneur.57.5.646 · Cited by 98
Transforming Growth Factor‐Beta
Frenz, D. A., Galinović-Schwartz, V., Staecker, H., & Water, T. R. V. D. (1991) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1991.tb19596.x · Cited by 85
Hormonal Regulation of Growth Plate Cartilage
Savendahl, L. S. (2005) · Hormone Research in Paediatrics · doi:10.1159/000087764 · Cited by 82
Absence of β-Amyloid Deposits After Immunization in Alzheimer Disease With Lewy Body Dementia
Bombois, S., Maurage, C., Gompel, M., Deramecourt, V., Mackowiak‐Cordoliani, M., Black, R. S., Lavielle, R., Delacourte, A., & Pasquier, F. (2007) · Archives of Neurology · doi:10.1001/archneur.64.4.583 · Cited by 71
Tian, J., Shi, J., Smallman, R., Iwatsubo, T., & Mann, D. M. A. (2006) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00732.x · Cited by 61
Prada, C. M., García-Alloza, M., Betensky, R. A., Zhang-Nunes, S., Greenberg, S. M., Bacskai, B. J., & Frosch, M. P. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.5426-06.2007 · Cited by 56
APOE and cerebral amyloid angiopathy in the elderly
Love, S., Nicoll, J. A. R., Hughes, A., & Wilcock, G. K. (2003) · Neuroreport · doi:10.1097/00001756-200308060-00027 · Cited by 53
Self-citationPrevention and Reduction of AD‐type Pathology in PDAPP Mice Immunized with Aβ1–42
Games, D., Bard, F., Grajeda, H., Guido, T., Khan, K., Soriano, F., Vasquez, N. J., Wehner, N., Johnson‐Wood, K., Yednock, T. A., et al. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06936.x · Cited by 50
Zhang, W.-W., Lempessi, H., & Olsson, Y. (1998) · Acta Neuropathologica · doi:10.1007/s004010050935 · Cited by 39
Apolipoprotein E Alleles and Brain Vascular Pathology in Alzheimer's Diseasea
Kalaria, R. N., Cohen, D., & Premkumar, D. R. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb34430.x · Cited by 29
Jellinger, K. A. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01412.x · Cited by 14
Institute of Child Health, London, UK 12‐14 January 2005
Révész, T. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00644.x · Cited by 4
Cited by
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Self-citationThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Microglia in neurodegenerative disease
Perry, V. H., Nicoll, J. A. R., & Holmes, C. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17 · Cited by 1,543
Self-citationCerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0281-2 · Cited by 947
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
Metadata
- Authors
- Boche, D., Zotova, E., Weller, R. O., Love, S., Neal, J. W., Pickering, R. M., Wilkinson, D., Holmes, C., & Nicoll, J. A. R.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-10-25
- Volume
- 131
- Issue
- 12
- Pages
- 3299-3310
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2148034536
- Cited by
- 316
- References
- 73
- FWCI
- 15.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.